Trials / Sponsors / Cellectis S.A.
Cellectis S.A.
Industry · 6 registered clinical trials — 2 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma B-cell Non-Hodgkin Lymphoma (B-NHL) | Phase 1 / Phase 2 | 2022-11-01 |
| Terminated | Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myel Relapsed/Refractory Multiple Myeloma | Phase 1 | 2019-11-21 |
| Recruiting | Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia ( B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | 2019-10-14 |
| Withdrawn | Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia Acute Myeloid Leukaemia | Phase 1 | 2019-07-11 |
| Terminated | Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Phase 1 | 2017-06-28 |
| Active Not Recruiting | Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukem Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | 2017-06-19 |